Drug reference

Gemtuzumab ozogamicin

Monoclonal Antibody · Antineoplastic

Also known as MYLOTARG

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

and reproductive function in

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Gemtuzumab ozogamicin is a humanized monoclonal antibody linked to a cytotoxic agent (ozogamicin), classifying it as an immunotoxin. It specifically targets and binds to CD33-expressing tumor cells. Upon binding, it induces cell cycle arrest and subsequent apoptotic cell death in these malignant cells.

Indications

CD33-positive acute myeloid leukaemia (specialist use only)CD33-positive AML

Dosing

Adult: l INDICATIONS AND DOSE Immune system and malignant disease 8 Multiple myeloma in patients who have received at least one prior therapy (in combination with lenalidomide and dexamethasone) (specialist use only) Gemtuzumab ozogamicin 17-Oct-2018 Gemtuzumab ozogamicin is a monoclonal antibody that binds to CD33-expressing tumour cells to induce cell cycle arrest and apoptotic cell death.…

Pharmacokinetics

Half-life

total calicheamicin 41 hours, unconjugated 143 hours; drug-antibody conjugate increases to 64 hours after second dose

Side effects

Serious

myelosuppression
hepatocellular damage (hyperbilirubinemia and enzyme elevations)
hepatic veno-occlusive disease (when patients subsequently undergo myeloablative therapy or when treatment follows high-dose chemotherapy)